Stay updated on Lete-cel Immunotherapy Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Lete-cel Immunotherapy Combo in NSCLC Clinical Trial page.

Latest updates to the Lete-cel Immunotherapy Combo in NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe record presents details for the letetresgene autoleucel study in advanced non-small cell lung cancer, including its terminated status, eligibility criteria, locations, study arms, outcomes, results, and supporting documents.SummaryDifference73%

- Check11 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov release as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA notice about NIH’s transition from “Artificial Intelligence” to “Super Intelligence” was added above the page, and the site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check39 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe study page now displays a 403 Forbidden error, blocking access to the record and indicating a site access issue rather than new content.SummaryDifference20%

- Check60 days agoChange DetectedThe page revision tag was updated from v3.6.6 to v3.7.0, indicating a new page version; this update does not modify the study content or results.SummaryDifference0.0%

Stay in the know with updates to Lete-cel Immunotherapy Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lete-cel Immunotherapy Combo in NSCLC Clinical Trial page.